Journal
PHARMACEUTICALS
Volume 16, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/ph16091194
Keywords
AChE/BChE; Alzheimer's disease; neurodegenerative disorders; antioxidants; donepezil; melatonin; neuroprotection; SH-SY5Y; Neuro-2a; BBB; molecular docking; MT1 and MT2
Categories
Ask authors/readers for more resources
This study developed novel hybrid molecules targeting the key pathogenetic mechanisms of Alzheimer's disease (AD). The lead compounds exhibited promising multifunctional activity against AD-related neurodegenerative mechanisms, including inhibition of acetylcholinesterase (AChE), strong antioxidant activity, and protection against oxidative stress. These compounds also demonstrated low neurotoxicity and the ability to penetrate the blood-brain barrier, making them potential prototypes for the treatment of AD-associated neurodegeneration with oxidative stress.
Alzheimer's disease (AD) is considered a complex neurodegenerative condition which warrants the development of multitargeted drugs to tackle the key pathogenetic mechanisms of the disease. In this study, two novel series of melatonin- and donepezil-based hybrid molecules with hydrazone (3a-r) or sulfonyl hydrazone (5a-l) fragments were designed, synthesized, and evaluated as multifunctional ligands against AD-related neurodegenerative mechanisms. Two lead compounds (3c and 3d) exhibited a well-balanced multifunctional profile, demonstrating intriguing acetylcholinesterase (AChE) inhibition, promising antioxidant activity assessed by DPPH, ABTS, and FRAP methods, as well as the inhibition of lipid peroxidation in the linoleic acid system. Compound 3n, possessing two indole scaffolds, showed the highest activity against butyrylcholinesterase (BChE) and a high selectivity index (SI = 47.34), as well as a pronounced protective effect in H2O2-induced oxidative stress in SH-SY5Y cells. Moreover, compounds 3c, 3d, and 3n showed low neurotoxicity against malignant neuroblastoma cell lines of human (SH-SY5Y) and murine (Neuro-2a) origin, as well as normal murine fibroblast cells (CCL-1) that indicate the in vitro biocompatibility of the experimental compounds. Furthermore, compounds 3c, 3d, and 3n were capable of penetrating the blood-brain barrier (BBB) in the experimental PAMPA-BBB study. The molecular docking showed that compound 3c could act as a ligand to both MT1 and MT2 receptors, as well as to AchE and BchE enzymes. Taken together, those results outline compounds 3c, 3d, and 3n as promising prototypes in the search of innovative compounds for the treatment of AD-associated neurodegeneration with oxidative stress. This study demonstrates that hydrazone derivatives with melatonin and donepezil are appropriate for further development of new AChE/BChE inhibitory agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available